Literature DB >> 4006050

Studies on the mechanism of cytotoxicity of 3-deazaguanosine in human cancer cells.

T Page, S J Jacobsen, R M Smejkal, J Scheele, W L Nyhan, J H Mangum, R K Robins.   

Abstract

The mechanism of toxicity of 3-deazaguanosine was studied in a number of human tumor cell lines by determination of the effects of various purine compounds on the growth of the cells in the presence of the drug and by studies of the effects of 3-deazaguanosine on the metabolism of radiolabeled precursors in these cells. The drug was found to be toxic to all of the cell lines tested. The toxicity was reversible with removal of the drug. None of the purine bases tested could restore normal growth after 48 h exposure to 3-deazaguanosine; the bases were more effective in preventing cytotoxicity when added simultaneously with the drug. Metabolic studies indicated decreased synthesis of DNA, variable inhibition of de novo purine synthesis, and complete inhibition of the enzyme guanosine monophosphate reductase by 3-deazaguanosine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006050     DOI: 10.1007/bf00257296

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Guanosine triphosphate catabolism in human and rabbit erythrocytes: role of reductive deamination of guanylate to inosinate.

Authors:  J F Henderson; G Zombor; P W Burridge
Journal:  Can J Biochem       Date:  1978-06

2.  Action of 3-deazaguanine in Escherichia coli.

Authors:  P P Saunders; L Y Chao; R K Robins; T L Loo
Journal:  Mol Pharmacol       Date:  1979-05       Impact factor: 4.436

3.  Inhibition of purine metabolism--computer-assisted analysis of drug effects.

Authors:  F F Snyder; J F Henderson; D A Cook
Journal:  Biochem Pharmacol       Date:  1972-09-01       Impact factor: 5.858

4.  7-Ribosyl-3-deazaguanine--mechanism of antibacterial action.

Authors:  D G Streeter; M Miller; T R Matthews; R K Robins; J P Miller
Journal:  Biochem Pharmacol       Date:  1980-06-15       Impact factor: 5.858

5.  Actions of 3-deazaguanine and 3-deazaguanosine on variant lines of Chinese hamster ovary cells.

Authors:  P P Saunders; L Y Chao; T L Loo; R K Robins
Journal:  Biochem Pharmacol       Date:  1981-08-15       Impact factor: 5.858

6.  Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors.

Authors:  P D Cook; L B Allen; D G Streeter; J H Huffman; R W Sidwell; R K Robins
Journal:  J Med Chem       Date:  1978-12       Impact factor: 7.446

7.  Analysis of radioactive and nonradioactive purine bases, nucleosides, and nucleotides by high-speed chromatography on a single column.

Authors:  B Bakay; E Nissinen; L Sweetman
Journal:  Anal Biochem       Date:  1978-05       Impact factor: 3.365

8.  Pyrimidine nucleotide metabolism in L5178Y murine leukemia cells: deoxycytidine protection from deoxyguanosine toxicity.

Authors:  J C Theiss; N R Morris; G A Fischer
Journal:  Cancer Biochem Biophys       Date:  1976-05

9.  3-Deazaguanine: inhibition of initiation of translation in L1210 cells.

Authors:  R S Rivest; D Irwin; H G Mandel
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

10.  3-deazaguanine, a candidate drug for the chemotherapy of breast carcinomas?

Authors:  T A Khwaja
Journal:  Cancer Treat Rep       Date:  1982-10
View more
  2 in total

1.  Cloning and functional characterization of GMPR2, a novel human guanosine monophosphate reductase, which promotes the monocytic differentiation of HL-60 leukemia cells.

Authors:  Jia Zhang; Weiping Zhang; Dajin Zou; Guoyou Chen; Tao Wan; Minghui Zhang; Xuetao Cao
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-01       Impact factor: 4.553

2.  Synthesis of 2'-O-methyl-RNAs incorporating a 3-deazaguanine, and UV melting and computational studies on its hybridization properties.

Authors:  Kohji Seio; Takeshi Sasami; Ryuya Tawarada; Mitsuo Sekine
Journal:  Nucleic Acids Res       Date:  2006-08-26       Impact factor: 16.971

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.